This video demonstrates the combined femoral and sciatic nerve blocks in patients undergoing major lower extremity amputations (MLEA), such as above-knee (AKA) or below-knee (BKA) amputations. These patients often have multiple comorbidities, including diabetes, cardiovascular, and renal disorders, making them poor candidates for general, and sometimes even spinal anesthesia due to heightened risks of postoperative complications, and/or risk of spinal hematoma. In the video, we combined these blocks with liposomal bupivacaine (Exparel®) to extend the analgesic benefits even much longer into the postoperative period, as documented in a study by Schwartz and colleagues.
Here are the Key Insights from the Video:
1. High Mortality Rates Post-MLEA: Research shows a 20% mortality rate within 30 days and nearly 50% within a year following MLEA. Our techniques aim to mitigate these risks.
2. Objective of Anesthetic Management: We focus on minimizing anesthetic risks while providing effective postoperative analgesia. This approach not only alleviates patient suffering but also promotes early mobilization.
3. Benefits of Combined Nerve Blocks: The use of subgluteal sciatic and femoral nerve blocks during surgeries for lower extremity amputation maintains stable hemodynamics and reduces the risk of intraoperative and postoperative morbidity.
4. Enhancement with Exparel: We incorporate Exparel in approved indications for sciatic and femoral blocks, optimizing anesthesia and improving outcomes for our most vulnerable patients.
GET YOUR COPY OF NERVE BLOCK MANUAL DELUXE!
community.nyso...
Where else to find us:
Web- www.nysora.com
Instagram- / nysora.inc
LinkedIN- / nysora-inc
Facebook- / nysora
Twitter- / nysora
TikTok- / nysora_inc
---------------------------------------------------------
#nysora #regionalanesthesia #anesthesia
Disclaimer:
Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's RU-vid channel is accurate.
30 сен 2024
